Narcotic Drugs

The Politics of Narcotic Drugs brings together leading experts on the drugs trade to provide an accessible yet detailed analysis of the multiple challenges that the contemporary trade in narcotic drugs and its prohibition pose, from the local to the international community. Through the use of country and regional case studies that include Afghanistan, Mexico, Colombia and the Middle East, the drivers of the drugs trade and the security and development dilemmas created by the prohibition of narcotic substances are explored. Contributions that assess the international drug control regime, British anti-drug enforcement organizations, 'narcoterrorism' and options for drug policy reform engage readers in current debates and the narrative frameworks that shape discussion of the drugs issue. The book is an invaluable guide to the dynamic and far-reaching issue of narcotic drugs and the impact of their prohibition on our countries and communities. The chapters are followed by an A-Z glossary of key terms, issues and organizations, and a section of maps and statistics.

This book uncovers the mysterious aura surrounding drugs o provide answers to questions like what are they, why do they entrap a person in their clutches and how we can stay free of their mind altering effects.

To this day, the perception persists that China was a civilization defeated by imperialist Britain's most desirable trade commodity, opium—a drug that turned the Chinese into cadaverous addicts in the iron grip of dependence. Britain, in an effort to reverse the damage caused by opium addiction, launched its own version of the "war on drugs," which lasted roughly sixty years, from 1880 to World War II and the beginning of Chinese communism. But, as Narcotic Culture brilliantly shows, the real scandal in Chinese history was not the expansion of the drug trade by Britain in the early nineteenth century, but rather the failure of the British to grasp the consequences of prohibition. In a stunning historical reversal, Frank Dikötter, Lars Laamann, and Zhou Xun tell this different story of the relationship between opium and the Chinese. They reveal that opium actually had few harmful effects on either health or longevity; in fact, it was prepared and appreciated in highly complex rituals with inbuilt constraints preventing excessive use. Opium was even used as a medicinal panacea in China before the availability of aspirin and penicillin. But as a result of the British effort to eradicate opium, the Chinese turned from the relatively benign use of that drug to heroin, morphine, cocaine, and countless other psychoactive substances. Narcotic Culture provides abundant evidence that the transition from a tolerated opium culture to a system of prohibition produced a "cure" that was far worse than the disease. Delving into a history of drugs and their abuses, Narcotic Culture is part revisionist history of imperial and twentieth-century Britain and part sobering portrait of the dangers of prohibition.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.